[{"id":"28905f7c-1ba3-4c54-b0ee-8bfef8ba9fd0","acronym":"CDFF332A12101","url":"https://clinicaltrials.gov/study/NCT04895748","created_at":"2021-05-20T11:54:08.339Z","updated_at":"2024-07-02T16:35:03.755Z","phase":"Phase 1","brief_title":"DFF332 as a Single Agent and in Combination With Everolimus \u0026 Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer \u0026 Other Malignancies","source_id_and_acronym":"NCT04895748 - CDFF332A12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2","pipe":" | ","alterations":" VHL mutation • SDHB mutation","tags":["VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation • SDHB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-14"}]